AG
RVNC

Aperio Group’s Revance Therapeutics, Inc. RVNC Stock Holding History

Aperio Group’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$1.23M Buy
43,528
+522
+1% +$13.5K ﹤0.01% 1472
2020
Q3 		$1.08M Sell
43,006
-1,679
-4% -$44K ﹤0.01% 1412
2020
Q2 		$1.09M Sell
44,685
-4,340
-9% -$85.7K ﹤0.01% 1373
2020
Q1 		$725K Sell
49,025
-2,952
-6% -$61.1K ﹤0.01% 1440
2019
Q4 		$844K Buy
51,977
+7,694
+17% +$119K ﹤0.01% 1517
2019
Q3 		$575K Buy
44,283
+9,732
+28% +$119K ﹤0.01% 1681
2019
Q2 		$448K Buy
34,551
+21,570
+166% +$272K ﹤0.01% 1848
2019
Q1 		$205K Buy
+12,981
New +$225K ﹤0.01% 2152

Other funds holding RVNC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Aperio Group's RVNC Position: Q4 2020 in Review

Aperio Group increased its Revance Therapeutics, Inc. (RVNC) stake by 1.2% in Q4 2020, buying an estimated $13.5K and bringing the position to 43,528 shares worth $1.23M. The position accounts for ﹤0.01% of the portfolio, ranked #1472.

Aperio Group first reported a position in RVNC in Q1 2019 and has held it in 8 quarters since. 151 funds tracked by Wall St. Rank hold RVNC as of Q4 2020.

  • Aperio Group held 43,528 shares of Revance Therapeutics, Inc. worth $1.23M as of Q4 2020.
  • Aperio Group bought 522 Revance Therapeutics, Inc. shares in Q4 2020, an estimated $13.5K.
  • Revance Therapeutics, Inc. made up ﹤0.01% of Aperio Group's portfolio in Q4 2020, its #1472 holding.
  • Aperio Group first reported a position in Revance Therapeutics, Inc. in Q1 2019 and has held it in 8 quarters since.
  • 151 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2020.

Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.